GlassScriptPhysician profile
John L Wood
NPI 1396764429
$1,689.56
in general payments reported to CMS, 2019-2025
19 companies · $292 in 2025
The $292 reported for 2025 was more than what 88% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $241 · 2021: $339 · 2022: $206 · 2023: $120 · 2024: $113 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $388.92 | 2021-2025 | Dalvance |
| Ge Healthcare | $217.68 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $165.15 | 2019-2025 | Eliquis |
| Mindray Ds USA, INC. | $123.30 | 2025 | Te7 Max, Te X |
| Astrazeneca Pharmaceuticals LP | $112.78 | 2019-2025 | Fasenra |
| Janssen Pharmaceuticals, INC | $102.20 | 2020-2022 | |
| Vapotherm INC | $94.24 | 2020 | |
| Portola Pharmaceuticals, LLC | $80.54 | 2019 | |
| Csl Behring | $79.24 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $58.29 | 2022-2023 | Ultomiris |
| Genentech USA, INC. | $51.97 | 2019-2020 | |
| Allergan, INC. | $40.85 | 2019-2020 | |
| Chiesi USA, INC. | $37.65 | 2019-2024 | Cleviprex |
| Pfizer INC. | $32.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $26.66 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Btg International INC. | $24.28 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $23.34 | 2024 | |
| Bioxcel Therapeutics, INC. | $19.80 | 2023 | Igalmi |
| Rare Disease Therapeutics, INC. | $10.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.